Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer

  • Innate Pharma SA IPHA presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab in patients with advanced Sézary syndrome, a form of T cell lymphoma. 
  • At the time of data cut-off (April 29, 2022), the Intention To Treat (ITT1) population included 37 post-mogamulizumab patients, and 35 patients were Evaluable for Efficacy (EES2). 
  • Related: AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer.
  • The global objective response rate (ORR) in the ITT population was 21.6% (8/37). ORR in the blood was 37.8%, with 21.6% (8/37) achieving complete response (CR). ORR in the skin was 35.1%. 
  • In the EES population, global ORR was 22.9% (8/35). ORR in the blood was 40.0%, and ORR in the skin was 37.1%.
  • In line with previous observations, lacutamab demonstrated a favorable safety profile. 
  • Grade ≥ 3 Treatment-related (TR) Treatment-Emergent Adverse events (TEAEs) were observed in 6/37 (16.2%) patients. 
  • Price Action: IPHA shares are up 4.72% at $2.22 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!